Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01208766
Show Display Options
Rank Status Study
1 Recruiting Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib, Melphalan, Prednisone (VMP);   Drug: 1 or 2 cycle(s) HDM (High Dose Melphalan);   Drug: 2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)

Indicates status has not been verified in more than two years